News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Health Canada approves Moderna's mRESVIA, a single-dose mRNA vaccine against RSV for adults aged 60 and older in a convenient pre-filled syringe. The vaccine's approval follows successful Phase 3 trial ConquerRSV -
-
-
COMMUNIQUÉ DE PRESSE
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q3 revenue of $1.9B, net income of $13M, and EPS of $0.03. Initiates Phase 3 trials for mRNA vaccines, reiterates 2024 sales guidance. Announces expansion of Executive Committee -
